---
schema_version: "secwatch.filing_event.v1"
accession: "0001731122-24-001372"
form_type: "8-K"
ticker: "LNAI"
cik: "0001527728"
company_name: "Lunai Bioworks Inc."
filed_at: "2024-09-11T23:59:59+00:00"
generated_at: "2026-05-31T05:25:59.215277+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# Renovaro seeks strategic investors for up to 20% of subsidiary Cube

## Summary
- Board intends to offer up to 20% ownership in RenovaroCube, a wholly owned molecular data science subsidiary.
- Cube uses proprietary AI for multi-omics analysis to accelerate precision medicine, starting with cancer.
- Proceeds from the offering expected to advance Cube's platform and go-to-market strategy.
- Subscription terms to be determined as investors are identified and approved by Renovaro's Board.
- RenovaroBio continues work on patented cancer vaccine targeting pancreatic, head and neck, liver tumors.

## SEC filing metadata
- accession: 0001731122-24-001372
- form_type: 8-K
- ticker: LNAI
- cik: 0001527728
- company_name: Lunai Bioworks Inc.
- filed_at: 2024-09-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527728/000173112224001372/0001731122-24-001372-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527728/000173112224001372/e5928_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001731122-24-001372
- JSON: https://secwatch.observer/filing/0001731122-24-001372.json
- Plain text: https://secwatch.observer/filing/0001731122-24-001372.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.